Research programme: anti-MICA monoclonal antibody - Innate Pharma

Drug Profile

Research programme: anti-MICA monoclonal antibody - Innate Pharma

Alternative Names: IPH-43; IPH-4301

Latest Information Update: 08 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innate Pharma
  • Class Monoclonal antibodies
  • Mechanism of Action Natural killer cell receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Mar 2017 Preclinical development is ongoing in France
  • 18 Apr 2016 Preclinical data presented at the American Association for Cancer Research (AACR-2016)
  • 18 Apr 2016 Innate Pharma plans a phase I trial for Cancer in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top